Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07643428 · ClinicalTrials.gov registry record · Phase 2

Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors

A Phase 2 study, sponsored by Medical College of Wisconsin.

Not yet
Registry status
Phase 2
Development phase
35
Enrollment target

NCT07643428 is a Phase 2 study that has not yet begun recruiting, run by Medical College of Wisconsin. The registered enrollment target is 35 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07643428, a Phase 2 study, has not yet begun recruiting, sponsored by Medical College of Wisconsin.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
35 participants
Enrollment target

Study Summary

This is a single-arm Phase 2 interventional treatment study to investigate changes in tissue lipidomes with omega-3 polyunsaturated fatty acids (PUFA) supplementation and correlations with pathological response in patients with early-stage breast cancer. Patients will be treated with a dietary supplement enriched with omega-3 PUFA (O3Supp) for 4 to 28 weeks prior to surgical resection of a breast tumor(s). Concurrent standard-of-care neoadjuvant treatment with clinically indicated systemic agents (such as chemotherapy, endocrine therapy, anti-HER2 therapy, immunotherapy) is allowed.

Interventions

  • DRUG Mini rTG OMEGA-3 Fish Oil

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2026-09-01
Est. Completion 2028-06-01
Phase Phase 2

Sponsor

Medical College of Wisconsin

447 total trials

What the Registry Record Tells You About NCT07643428

The ClinicalTrials.gov registry entry for NCT07643428 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Mini rTG OMEGA-3 Fish Oil is the first listed.

NCT07643428 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07643428 about?

NCT07643428 is a clinical study titled "Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors". This is a single-arm Phase 2 interventional treatment study to investigate changes in tissue lipidomes with omega-3 polyunsaturated fatty acids (PUFA) supplementation and correlations with pathological response in patients with early-stage breast cancer. Patients will be treated with a dietary suppl...

What is the current status of trial NCT07643428?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2026-09-01. Estimated completion is 2028-06-01.

What interventions are being tested in trial NCT07643428?

The interventions under investigation include: Mini rTG OMEGA-3 Fish Oil (DRUG).

Who is sponsoring clinical trial NCT07643428?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.